Mike Dastoor
Analyst · Raymond James. Your line is now live
Thanks, Adam. Good morning, everyone. Thank you for joining us today. As Adam stated, our Q2 results were negatively impacted by the COVID-19 outbreak. Before I cover our Q2 results, I'd like to take a moment to walk you through the dynamics that unfolded during the quarter. We began Q2 with a stronger-than-anticipated start to the fiscal quarter. As we moved into February, demand held, but our ability to meet demand was greatly diminished as virus containment efforts ramped in China. during the quarter, we incurred approximately $53 million in direct costs associated with the COVID-19 outbreak. I'd now like to provide you with the makeup of these costs. First, we incurred additional labor costs in Q2. During February, we strategically made the decision to compensate our employees who are restricted and quarantined. These factors contributed to higher labor costs than we expected going into the quarter. Second, our factory utilization in China was negatively impacted in February due to travel disruptions and restrictions. To add further context to the higher labor costs and lower utilization, February began with the Chinese New Year holiday being extended by 10 to 14 days depending on location. Most of our larger sites in China began to come back online later than anticipated. And by February 14, we were only operating at 45% to 50% capacity. We exited the quarter at approximately 80% utilization in China. Third, during the quarter, we also incurred lost revenue associated with both upstream and downstream supply chain disruptions, which impacted our worldwide footprint. And finally, in an effort to keep our employee base safe and healthy, we incurred unanticipated costs to procure necessary supplies to keep our people safe, items, such as face masks, hand sanitizers, thermometers and personal protection equipment. I would like to highlight that February was an anomaly. Under normal circumstances, if demand diminished, our variable costs would have been materially lower as we would have adjusted our costs to the demand environment. Turning now to our Q2 financial results. Net revenue for the second quarter was $6.1 billion. GAAP operating income was $91 million, and our GAAP diluted loss per share was $0.02. Core operating income during the quarter was $159 million. Net interest expense during the quarter was $52 million. Our core tax rate for the quarter was 26.6%, in-line with expectations. Core diluted earnings per share were $0.50. It's worth noting that the additional costs associated with the outbreak negatively impacted our diluted earnings per share by approximately $0.25. Now moving to our GAAP results. As expected, we incurred $30 million in restructuring and severance-related charges in Q2, predominantly associated with the 2020 restructuring plan we announced in September of last year. This plan continues to remain on track and as a reminder, is expected to result in an incremental cost savings benefit of $25 million, mainly in the second half of FY20. Also during the quarter, we incurred a onetime non-cash impairment charge of approximately $12 million in connection with the sale of an investment in the optical networking segment. Now turning to our second quarter segment results. Revenue for our DMS segment was $2.3 billion. From an end-market perspective, we experienced good demand in the health care and mobility end markets. Revenue for our EMS segment was $3.8 billion. From an end-market perspective, we saw additional strength in the semi cap space, while demand in the balance of the business came in largely as expected. Turning now to our cash flows and balance sheet. During Q2, our total days of inventory came in at 70 days, an increase of 13 days sequentially, driven mainly by idle capacity and supply chain constraints due to COVID-19. Higher inventory levels during the quarter were offset slightly by lower days of sales outstanding at the end of the quarter, driven mainly by lower February sales. Cash flows provided by operations were $63 million in Q2, and net capital expenditures totaled $205 million. We exited the quarter with a total debt to core EBITDA level of approximately 1.7x and cash balances of $697 million. Jabil has over $3 billion of global revolver credit facilities, and at the end of Q2, over 90% of these facilities were available. During Q2, we repurchased approximately 1.8 million shares for $72 million as part of our two year, $600 million authorization we announced in September. In closing, as always, Jabil's No.1 priority is the health and well-being of our employees. We are also focused on providing the best possible service to our customers. We take our responsibility as a global corporate citizen very seriously. These values motivate our teams to take significant measures to prevent the spread of COVID-19 and minimize business disruption in this very challenging environment. I'll now turn the call over to Adam.